Shaping a Path to Discovery
Takeda focuses on a variety of therapeutic areas including cardiovascular/metabolic, central nervous system, immunology and respiratory, and oncology.
Learn more about Takeda products and review the associated complete prescribing information.
Takeda Global Research & Development Center, Inc. (TGRD) dedicates its resources to the Takeda product pipeline in an effort to deliver innovative medicines to patients. As a research-based pharmaceutical company, efforts are currently focused on pre-clinical work and clinical development activities in the United States.
Our commitment to bringing superior pharmaceutical products to market is enhanced by our close strategic relationship with the entire Takeda family of companies. Collaborating in the earliest stages of a compound’s development ensures effective product lifecycle management and sensitivity to patient needs.
The Takeda family of companies works in tandem to explore new areas of medicine and bring the power of next generation science to bear in existing health conditions.
Our collaborative partners adhere to Good Clinical Practices (GCP), federal requirements, and international guidelines in conducting clinical trials to protect the rights and welfare of our study participants and the validity of the study data. We have adopted the Pharmaceutical Research and Manufacturers of America (PhRMA) code of integrity, compliance, and social responsibility. We also follow Good Manufacturing and Good Laboratory Practices (GMP and GLP).
Please see the chart below for compounds in development in the U.S.
|vortioxetine (Lu AA21004)
||Ulcerative colitis and Crohn’s disease
||Type 2 diabetes
Clinical Trial Information
Clinical trials are research studies conducted on new drugs or treatments in the pharmaceutical industry to test if they are safe and effective for patients. The clinical trial seeks to answer questions and find solutions to provide patients the safest, best treatments for a disease or illness.
Clinical trials depend on people who volunteer to try a new drug or treatment. In some cases, a drug has not yet been approved by the U.S. Food and Drug Administration (FDA) to be sold in the United States. Or, the drug may have been approved, but it is being tested for a different treatment or additional information.
There are four different phases of clinical development:
- Phase 1: This type of trial involves a small group of people (20-80) and it is the first time the drug is tested in people. Researchers study whether the drug is safe and identify side effects and safe dosage amounts. This phase usually includes healthy volunteer subjects.
- Phase 2: This type of trial involves a greater number of participants (100-300); it is typically the first time the drug is tested in a patient population for which the drug is being developed. The primary purpose for this type of trial is to assure the drug's effectiveness in the patient population for which it is intended. Researchers continue to study the drug's safety during this phase.
- Phase 3: During this phase of clinical development, trials usually involve a large group of people (1,000-3,000). Researchers evaluate how the patients are reacting to the drug, evaluating whether the drug is helping treat the patient as it should, monitoring additional effects, comparing it to commonly used treatments, and continuing to study ways for the drug to be used safely.
- Phase 4: Commonly called "post-marketing studies" this phase is a continued focus on the drug's safety, effectiveness, and best usage.
Click here for a Glossary of clinical trial terms
Click here for FAQs on clinical trials